This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wheeler, C. J. Articles by Yu, J. S. Search for Related Content PubMed PubMed Citation Articles by Wheeler, C. J. Articles by Yu, J. S.

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

¹ Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, and ² Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

Requests for reprints: Christopher J. Wheeler, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048. Phone: 310-423-6646; Fax: 310-423-0302; E-mail: wheelerc{at}cshs.org.

Key Words: glioma • immunotherapy • vaccine

Cancer vaccine trials have failed to yield robust immune-correlated clinical improvements as observed in animal models, fueling controversy over the utility of human cancer vaccines. Therapeutic vaccination represents an intriguing additional therapy for glioblastoma multiforme (GBM; grade 4 glioma), which has a dismal prognosis and treatment response, but only early phase I vaccine trial results have been reported. Immune and clinical responses from a phase II GBM vaccine trial are reported here. IFN- responsiveness was quantified in peripheral blood of 32 GBM patients given therapeutic dendritic cell vaccines. Posttreatment times to tumor progression (TTP) and survival (TTS) were compared in vaccine responders and nonresponders and were correlated with immune response magnitudes. GBM patients (53%) exhibited 1.5-fold vaccine-enhanced cytokine responses. Endogenous antitumor responses of similar magnitude occurred in 22% of GBM patients before vaccination. Vaccine responders exhibited significantly longer TTS and TTP relative to nonresponders. Immune enhancement in vaccine responders correlated logarithmically with TTS and TTP spanning postvaccine chemotherapy, but not with initial TTP spanning vaccination alone. This is the first report of a progressive correlation between cancer clinical outcome and T-cell responsiveness after therapeutic vaccination in humans and the first tracing of such correlation to therapeutically exploitable tumor alteration. As such, our findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans. [Cancer Res 2008;68(14):5955–64]

This article has been cited by other articles:

				N. Ahmed, V. S. Salsman, Y. Kew, D. Shaffer, S. Powell, Y. J. Zhang, R. G. Grossman, H. E. Heslop, and S. Gottschalk HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors Clin. Cancer Res., January 15, 2010; 16(2): 474 - 485. [Abstract] [Full Text] [PDF]

				J. H. Sampson, G. E. Archer, D. A. Mitchell, A. B. Heimberger, J. E. Herndon II, D. Lally-Goss, S. McGehee-Norman, A. Paolino, D. A. Reardon, A. H. Friedman, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme Mol. Cancer Ther., October 1, 2009; 8(10): 2773 - 2779. [Abstract] [Full Text] [PDF]

				A.K.M. Ghulam Muhammad, M. Candolfi, G. D. King, K. Yagiz, D. Foulad, Y. Mineharu, K. M. Kroeger, K. A. Treuer, W. S. Nichols, N. S. Sanderson, et al. Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression Clin. Cancer Res., October 1, 2009; 15(19): 6113 - 6127. [Abstract] [Full Text] [PDF]

				K. Itoh, A. Yamada, T. Mine, and M. Noguchi Recent Advances in Cancer Vaccines: An Overview Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 73 - 80. [Abstract] [Full Text] [PDF]